Cui Cui

Cui Cui joined Jefferies in Sep 2024, as head of Asia (ex. JP ex. AUS) healthcare. She comes with rich experience in the healthcare space for 11 years. She spent three years at UBS Asset Management as a healthcare senior analyst, where she led the launch of UBS China Healthcare Equity Fund. Prior to that, she was at Citigroup as Head of China Healthcare Research, during which time she led a No.1 ranking team in Institutional Investor Asia Healthcare five-year-in-a-row from 2017 to 2021. Cui also worked for Macquarie Securities and Johnson & Johnson Emerging Market Innovation Centre before. Cui majored in Biological Sciences in Fudan University, and was an exchange scholar in Yale Medical School.

What I am Known For

• Good market sense, extensive industry knowledge, good corporate access
• Flexibilty in recommendations and ideas, factoring in near-term catalysts and structural shifts.
• Sector knowledge and historical modeling

How I am Different

• We think the negatives from BIOSECURE
  Act are fully priced in, considering the passage of the Act has been highly anticipated by investors. Meanwhile, we view positively customer stickiness remaining high despite geopolitical concerns, largely due to the cost efficiency and proven FDA track record offered by Wuxi Group. Top Buy: Wuxi Bio.
• 
  We are cautious on: 1) Core product Ganmaoling (~40% of CR Sanjiu profit) being exposed to GPO risk; 2) Same-price policy and price comparison system to facilitate price consistency despite GPO progress; 3) Sizable M&As no longer a shortcut to subsidize growth, with less discretionary cash on hand after Tasly acquisitio
• Street-only co-cover by healthcare and consumer, better understanding on the transition from Consumer Cosmetics to Medical Beauty pla